EVX Ventures

Carmine Therapeutics is focused on developing a novel gene therapy platform that harnesses extracellular vesicles produced from red blood cells. This innovative approach aims to address limitations associated with traditional viral-based gene therapies, such as immunogenicity, small transgene capacity, and manufacturing challenges. The company's technology is designed to generate a diverse pipeline of gene therapies targeting hematology, oncology, and immunology, offering new treatment options for patients facing these medical conditions. By leveraging this proprietary platform, Carmine Therapeutics seeks to advance the development of a new class of medicines.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in patients with cardiovascular diseases. The firm specifically targets genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor aims to provide innovative solutions that enable healthcare professionals to effectively treat these conditions and improve heart health in affected individuals.